Johnson & Johnson ($JNJ) reports today in third-quarter financials that U.S. sales of OTC medicines were "significantly impacted" by the shutdown of McNeil's Consumer Healthcare manufacturing plant in Fort Washington, PA, the main player in its many Tylenol recalls over the last two years. In addition, ongoing remediation work lowered production volumes. Nonetheless, overall sales were up nearly 7% over last year's Q3. Release